AUTHORS
Chunmei Yang, Juying Wei2, Ying Lu3, Liping Mao4, Min Yang5, Huafeng Wang, MD6, Yinjun Lou7, Beili Hu8, Linjie Li9, Nengwen Xu10, Yanhong Tong11, Jie Jin, MD12, Wenjuan Yu13
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Yinzhou Hospital, Affiliated to College of Medicine, Ningbo University, Ningbo, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
9 Lishui central hospital, Lishui, China
10 Lishui central hospital, Lishui, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma, predominantly diffuse large B-cell lymphomas. High-dose methotrexate (HD-MTX) is the cornerstone of chemotherapy for newly diagnosed PCNSL. Orelabrutinib is a novel BTKi with high blood-brain barrier permeability and has demonstrated efficacy on PCNSL with minimal off-target effects and higher safety.
Aims
This study aimed to evaluate the efficacy and safety of a combination regimen consisting of ORT, with or without HD-MTX, in untreated PCNSL patients (pts).
Methods
This prospective, multicenter, single-arm study enrolled untreated PCNSL pts (≥18 years) who received ORT therapy: orelabrutinib 150 mg/day orally, rituximab 375 mg/m2 intravenously on day 0, and thiotepa 40mg/m2 intravenously on day 1, in a 21-day cycle. HD-MTX (3.5g/m2 IV) was administered every 3 weeks to pts ≤60 years with normal renal function. After 4 cycles, pts with a response continued the same dose for up to 4 more cycles, with autologous stem cell transplantation (ASCT) recommended for those ≤60 years. Maintenance therapy with orelabrutinib continued until 2 years of treatment. Adverse events (AEs) were graded according to Standard 5.0 Common Terminology for Adverse Events. The primary endpoint was the objective response rate (ORR) with secondary endpoints including progression-free survival (PFS) and overall survival (OS).
Results
From August 2022 to May 2026, 45 untreated PCNSL pts were enrolled, with a median age of 61 years (range, 31-78 years). Among them, 57.8% were male. Next-generation sequencing (NGS) was performed on 29 pts, revealing that 72.4% (21/29) had MCD-like subtypes, 13.8% (4/29) had TP53 mutations, and 1 patient had the BN2 subtype. 28.9% (13/45) received ORT and 68.9% (31/45) received ORT+HD-MTX; One patient initially received one cycle of ORT+HD-MTX before switching to ORT. Among the 45 pts who completed all induction therapies, the ORR was 86.6% (39/45) with a CR rate of 84.4% (38/45). The median follow-up was 20.1 months, the median PFS was not reached, with 1- and 2-year PFS rates of 90.1% and 75.1%, respectively. The median OS was not reached, with 1- and 2-year OS rates of 92.2% and 84.9%, respectively. In the patient cohort treated with ORT, the ORR was 76.9% (10/13) with a CR rate of 76.9% (10/13). The median PFS was 33.0 months, with 1- , 2-, and 3-year PFS rates of 69.2%, 55.4%, and 27.7%, respectively. In the group receiving ORT+HD-MTX, the ORR was 90.3% (28/31) with a CR rate of 87.1% (27/31). The median PFS was not reached, and the 1- , 2-, and 3-year PFS rates were 89.5%, 83.5%, and 71.6%, respectively. Statistical analysis showed a trend toward improved PFS in the ORT+HD-MTX group compared with the ORT group, although the difference did not reach statistical significance (p=0.162). 34.2% (13/38) of CR pts who finished chemotherapy received ASCT. Among the 45 pts, 64.4% (29/45) experienced grade 1-2 adverse reactions; grade 3-4 adverse reactions occurred in 28.9% (13/45). The most common grade 3-4 adverse events were leukopenia and neutropenia.
Conclusion:
This study demonstrates that ORT plus HD-MTX can serve as the preferred regimen for patients ≤60 years of age, whereas ORT monotherapy represents a viable alternative for patients >60 years or with renal insufficiency; nevertheless, the rational use of MTX remains a critical determinant for achieving long-term cure in PCNSL.
DISCLOSURES
Chunmei Yang: No relevant conflicts of interest to declare.